Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.59 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.52 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | F9 | P00740 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7445953 | 0.85 | CYP4F2 (0.72) | CYP4F2CYP4A11MRGPRX4GSTP1NR4A2 | |
| SCHEMBL19947462 | 0.85 | PTGER4 (0.51) | CYP4F2CYP4A11PTGER4PTGER3MRGPRX4 | |
| SCHEMBL18076580 | 0.84 | PTGER4 (0.61) | PTGER4PTGER3MRGPRX4GSTP1NR4A2 | |
| SCHEMBL2137838 | 0.80 | MRGPRX4 (0.69) | CYP4F2CYP4A11MRGPRX4GSTP1NR4A2 | |
| SCHEMBL7710805 | 0.80 | PTGER4 (0.55) | CYP4F2CYP4A11PTGER4PTGER3MRGPRX4 | |
| SCHEMBL7817624 | 0.80 | GSTP1 (0.60) | CYP4F2CYP4A11PTGER4PTGER3MRGPRX4 | |
| SCHEMBL3683352 | 0.79 | MRGPRX4 (0.61) | CYP4F2CYP4A11MRGPRX4GSTP1NR4A2 | |
| SCHEMBL18076597 | 0.79 | HSD17B1 (0.53) | PTGER4PTGER3PTGER1PTGER2 | |
| SCHEMBL7346174 | 0.79 | MRGPRX4 (0.64) | CYP4F2CYP4A11MRGPRX4GSTP1NR4A2 | |
| SCHEMBL16346074 | 0.79 | GSTP1 (0.66) | CYP4F2CYP4A11PTGER4PTGER3MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3271320-B1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | VECTUS BIOSYSTEMS LTD (AU) | 2019-10-23 | — | — | EP | disclosed |
| EP-3271320-B1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | VECTUS BIOSYSTEMS LTD (AU) | 2019-10-23 | — | — | EP | disclosed |
| US-10035775-B2 | Compositions for the treatment of fibrosis and fibrosis-related conditions | VECTUS BIOSYSTEMS LIMITED (AU) | 2018-07-31 | — | — | US | disclosed |
| US-10035775-B2 | Compositions for the treatment of fibrosis and fibrosis-related conditions | VECTUS BIOSYSTEMS LIMITED (AU) | 2018-07-31 | — | — | US | disclosed |
| US-20180072682-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | VECTUS BIOSYSTEMS LIMITED (AU) | 2018-03-15 | — | — | US | disclosed |
| US-20180072682-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | VECTUS BIOSYSTEMS LIMITED (AU) | 2018-03-15 | — | — | US | disclosed |
| EP-3271320-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | Vectus Biosystems Limited (AU) | 2018-01-24 | — | — | EP | disclosed |
| WO-2016145479-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | VECTUS BIOSYSTEMS LIMITED (AU) | 2016-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035775-B2 | Compositions for the treatment of fibrosis and fibrosis-related conditions | MMP1, COL1A1, COL2A1 | CYP4F2 2003/4885CYP4A11 1194/4885PTGER4 616/4885 |
| US-20180072682-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | MMP1, COL1A1, COL2A1 | CYP4F2 2003/4885CYP4A11 1194/4885PTGER4 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.